We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

DIASORIN

DiaSorin develops, produces and commercializes diagnostic tests for a wide range of clinical areas. The company’s tes... read more Featured Products: More products

Download Mobile App




New Urinary Antigen Immunodiagnostic Assay Enables High-Throughput Qualitative Detection of Legionnaires' Disease

By LabMedica International staff writers
Posted on 18 Jul 2023
Print article
Image: The new LIAISON Legionella Urinary Ag assay is performed on the LIAISON CLIA analyzers (Photo courtesy of DiaSorin)
Image: The new LIAISON Legionella Urinary Ag assay is performed on the LIAISON CLIA analyzers (Photo courtesy of DiaSorin)

Legionnaires' Disease (LD), a severe form of atypical Community Acquired Pneumonia (CAP), is primarily caused by the Legionella species in patients needing hospitalization. L. pneumophila sg 1 is responsible for 50 to 80% of LD cases globally. Sg 4 and 6, along with L. longbeachae, L. micdadei, and L. bozemanii, contribute to the majority of the remaining non-L.pneumophila sg 1 LD cases. If misdiagnosed or left untreated, LD can quickly deteriorate, leading to increased mortality rates. The death rate from LD can reach 40-80% in untreated immuno-compromised patients, but can be reduced to 5-30% with accurate identification and proper case management. Now, a new assay improves the diagnosis of atypical pneumonia by providing precise identification of the LD.

DiaSorin (Saluggia, Italy) has introduced the novel LIAISON Legionella Urinary Antigen Immunodiagnostic Assay, approved in all countries recognizing the CE Mark, as a tool for diagnosing LD. The assay, which is conducted on the LIAISON CLIA analyzers, offers a highly automated solution for microbiology laboratories. Using a simple test procedure, LD can be identified in a mere 35 minutes, enabling prompt and focused antimicrobial treatment. The LIAISON Legionella Urinary Ag assay, with its innovative "dual-antigen" design, can detect two Legionella's antigens (LPS and PAL), enhancing its sensitivity and specificity. This empowers healthcare practitioners to accurately identify antigens of Legionella pneumophila and Legionella longbeachae.

"The launch of this new assay confirms our ability to position DiaSorin as a specialty player, able to provide innovative solutions with a high medical value," said Chen Even, Chief Commercial Officer of DiaSorin. "We are confident that our new assay will strongly contribute in discriminating etiological factors in severe atypical pneumonia."

Related Links:
DiaSorin 

New
Platinum Member
Flu SARS-CoV-2 Combo Test
OSOM® Flu SARS-CoV-2 Combo Test
Magnetic Bead Separation Modules
MAG and HEATMAG
POCT Fluorescent Immunoassay Analyzer
FIA Go
New
Gold Member
All-in-one Molecular Diagnosis System
Panall 8000

Print article
77 ELEKTRONIKA

Channels

Clinical Chemistry

view channel
Image: PhD student and first author Tarek Eissa has analyzed thousands of molecular fingerprints (Photo courtesy of Thorsten Naeser / MPQ / Attoworld)

Screening Tool Detects Multiple Health Conditions from Single Blood Drop

Infrared spectroscopy, a method using infrared light to study the molecular composition of substances, has been a foundational tool in chemistry for decades, functioning similarly to a molecular fingerprinting... Read more

Molecular Diagnostics

view channel
Image: Researchers have found the first evidence of testing for the alpha-synuclein protein in blood samples via seed amplification assay (Photo courtesy of Shutterstock)

Blood Test to Detect Alpha-Synuclein Protein Could Revolutionize Parkinson's Disease Diagnostics

Currently, Parkinson's disease (PD) is identified through clinical diagnosis, typically at a later stage in the disease's progression. There is a pressing need for an objective and quantifiable biomarker... Read more

Hematology

view channel
Image: The Truvian diagnostic platform combines clinical chemistry, immunoassay and hematology testing in a single run (Photo courtesy of Truvian Health)

Automated Benchtop System to Bring Blood Testing To Anyone, Anywhere

Almost all medical decisions are dependent upon laboratory test results, which are essential for disease prevention and the management of chronic illnesses. However, routine blood testing remains limited worldwide.... Read more

Immunology

view channel
Image: The blood test measures lymphocytes  to guide the use of multiple myeloma immunotherapy (Photo courtesy of 123RF)

Simple Blood Test Identifies Multiple Myeloma Patients Likely to Benefit from CAR-T Immunotherapy

Multiple myeloma, a type of blood cancer originating from plasma cells in the bone marrow, sees almost all patients experiencing a relapse at some stage. This means that the cancer returns even after initially... Read more

Pathology

view channel
Image: The AI model can distinguish different stages of DCIS from inexpensive and readily available breast tissue images (Photo courtesy of David A. Litman/Shutterstock)

AI Model Identifies Breast Tumor Stages Likely To Progress to Invasive Cancer

Ductal carcinoma in situ (DCIS) is a non-invasive type of tumor that can sometimes progress to a more lethal form of breast cancer and represents about 25% of all breast cancer cases. Between 30% and 50%... Read more

Industry

view channel
Image: Beckman Coulter will utilize the ALZpath pTau217 antibody to detect key biomarker for Alzheimer\'s disease on its DxI 9000 immunoassay analyzer (Photo courtesy of Beckman Coulter)

Beckman Coulter Licenses Alzpath's Proprietary P-tau 217 Antibody to Develop Alzheimer's Blood Test

Cognitive assessments have traditionally been the primary method for diagnosing Alzheimer’s disease, but this approach has its limitations as symptoms become apparent only after significant brain changes... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.